Escherichia coli Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Escherichia coli Infections - Pipeline Review, H2 2016

Escherichia coli Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Escherichia coli Infections - Pipeline Review, H2 2016
Published Nov 23, 2016
165 pages — Published Nov 23, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections Pipeline Review, H2 2016, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 31 and 24 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 14 molecules, respectively.Escherichia coli Infections.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious D

  
Source:
Document ID
GMDHC8693IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents211
  List of Tables111
  List of Figures121
Introduction131
  Global Markets Direct Report Coverage131
Escherichia coli Infections Overview141
Therapeutics Development152
  Pipeline Products for Escherichia coli Infections Overview151
  Pipeline Products for Escherichia coli Infections Comparative Analysis161
Escherichia coli Infections Therapeutics under Development by Companies172
Escherichia coli Infections Therapeutics under Investigation by Universities/Institutes192
Escherichia coli Infections Pipeline Products Glance212
  Clinical Stage Products211
  Early Stage Products221
Escherichia coli Infections Products under Development by Companies233
Escherichia coli Infections Products under Investigation by Universities/Institutes261
Escherichia coli Infections Companies Involved in Therapeutics Development2729
  Adenium Biotech ApS271
  Arsanis, Inc.281
  AstraZeneca Plc291
  AvidBiotics Corp301
  Cellceutix Corp311
  Debiopharm International SA321
  Emergent BioSolutions Inc331
  F. Hoffmann-La Roche Ltd341
  GangaGen Inc351
  Hsiri Therapeutics LLC361
  Johnson &Johnson371
  Melinta Therapeutics Inc381
  Merck &Co Inc391
  Microbiotix Inc401
  Nabriva Therapeutics AG411
  Navigen Pharmaceuticals, Inc.421
  Nosopharm SAS431
  Novabiotics Ltd441
  Omnia Molecular Ltd451
  Paratek Pharmaceuticals Inc461
  Pherecydes Pharma SA471
  Phico Therapeutics Ltd481
  Procarta Biosystems Limited491
  Sealife PHARMA GMBH501
  Sequoia Sciences Inc511
  Soligenix Inc521
  Syntiron LLC531
  Tetraphase Pharmaceuticals Inc541
  Varinel Inc551
Escherichia coli Infections Therapeutics Assessment569
  Assessment by Monotherapy Products561
  Assessment by Target572
  Assessment by Mechanism of Action592
  Assessment by Route of Administration612
  Assessment by Molecule Type632
Drug Profiles6593
  A-3APO Drug Profile651
  AA-139 Drug Profile661
  AM-8722 Drug Profile671
  ASN-4 Drug Profile681
  AvR2-V10 Drug Profile692
  BC-7634 Drug Profile711
  BC-9074 Drug Profile721
  BC-9529 Drug Profile731
  BC-9563 Drug Profile741
  BIZ-20131 Drug Profile751
  BIZ-20132 Drug Profile761
  BIZ-20133 Drug Profile771
  CA-824 Drug Profile781
  CC-1807 Drug Profile791
  Debio-1454 Drug Profile801
  Drugs for Bacterial Infections Drug Profile811
  dusquetide Drug Profile825
  Escherichia coli (whole cell) vaccine Drug Profile871
  Escherichia coli vaccine Drug Profile881
  Escherichia coli vaccine Drug Profile891
  ETEC [strain B7A] vaccine Drug Profile901
  ETEC vaccine Drug Profile911
  EV-035 Drug Profile922
  GN-4474 Drug Profile941
  GNEG SNARE Drug Profile951
  HT-07 Drug Profile961
  INX-201 Drug Profile971
  JNJ-63871860 Drug Profile982
  MBX-2319 Drug Profile1001
  MDN-0057 Drug Profile1012
  mirandamycin Drug Profile1031
  NBTI-5463 Drug Profile1041
  NOSO-95179 Drug Profile1051
  NP-432 Drug Profile1061
  omadacycline tosylate Drug Profile1076
  Onc-72 Drug Profile1131
  P-100031 Drug Profile1141
  Peptides for Infectious Diseases Drug Profile1151
  PMX-100 Drug Profile1161
  PMX-1091 Drug Profile1171
  PMX-1142 Drug Profile1181
  PMX-1241 Drug Profile1191
  PMX-1278 Drug Profile1201
  PMX-1363 Drug Profile1211
  PMX-1405 Drug Profile1221
  PMX-223 Drug Profile1231
  PMX-229 Drug Profile1241
  PMX-247 Drug Profile1251
  PMX-633 Drug Profile1261
  PMX-668 Drug Profile1271
  PMX-693 Drug Profile1281
  PMX-843 Drug Profile1291
  PP-0121 Drug Profile1302
  Proteins for Infectious Diseases Drug Profile1321
  PT-5 Drug Profile1331
  Recombinant Protein for Escherichia Coli Infections Drug Profile1341
  RX-05 Drug Profile1351
  RXP-873 Drug Profile1361
  SE-1 Drug Profile1371
  Shigetec Drug Profile1381
  SLP-0901 Drug Profile1391
  SLP-0905 Drug Profile1401
  Small Molecule for Malaria and Bacterial Infections Drug Profile1411
  Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease Drug Profile1421
  Small Molecules for Bacterial Infections and Lung Infection Drug Profile1431
  Small Molecules for Escherichia Coli Infections Drug Profile1441
  Small Molecules for Escherichia coli Infections Drug Profile1451
  Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile1461
  Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections Drug Profile1471
  Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections Drug Profile1481
  Small Molecules to Inhibit RecA for Bacterial Infections Drug Profile1491
  SPR-741 Drug Profile1501
  Synthetic Peptide for Gram-Negative Bacterial Infections Drug Profile1511
  Synthetic Peptide for Oncology and Infectious Disease Drug Profile1521
  Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease Drug Profile1531
  Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections Drug Profile1541
  Synthetic Peptides for Escherichia Coli Infections Drug Profile1551
  TP-6076 Drug Profile1561
  VAR-10100 Drug Profile1571
Escherichia coli Infections Dormant Projects1583
Escherichia coli Infections Discontinued Products1611
Escherichia coli Infections Product Development Milestones1622
  Featured News &Press Releases1621
    Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia coli using Monoclonal Antibody Technology1621
    Apr 16, 2015: Navigen Receives Phase I SBIR Grant to Support Development of Treatment for Infections Caused by Shiga Toxin-producing E. coli1621
    Sep 01, 2014: AA139, Adenium Clinical Product Candidate Against Multi-Drug Resistant Gram-Negative Bacteria to be Presented at ICAAC in Washington1631
Appendix1642
  Methodology1641
  Coverage1641
  Secondary Research1641
  Primary Research1641
  Expert Panel Validation1641
  Contact Us1641
  Disclaimer1651

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Escherichia coli Infections - Pipeline Review, H2 2016" Nov 23, 2016. Alacra Store. Mar 28, 2024. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Escherichia-coli-Infections-Pipeline-Review-H2-2016-2088-16868>
  
APA:
Global Markets Direct - Market Research. (2016). Escherichia coli Infections - Pipeline Review, H2 2016 Nov 23, 2016. New York, NY: Alacra Store. Retrieved Mar 28, 2024 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Escherichia-coli-Infections-Pipeline-Review-H2-2016-2088-16868>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.